Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Inhibition of acid sphingomyelinase increases SMN levels and connects sphingolipid metabolism to Spinal Muscular Atrophy

  • Brokate Llanos, Ana
  • Beltran Perelló, Maria
  • Garzón, Andrés
  • Garcera, Ana
  • Miralles, María
  • Celma Nos, Ferrán
  • Campoy López, Alejandro
  • Soler i Tatché , Rosa Ma.
  • Muñoz, Manuel
  • Pérez Pulido, Antonio
Spinal Muscular Atrophy (SMA) is a moderately rare disease that causes progressive motor neuron degeneration and presents the highest neonatal death rate of all human genetic diseases. It is associated with the deletion or mutation of the SMN1 gene, encoding the SMN protein, mainly involved in the assembly of a ribonucleoprotein complex called Sm ring, essential for the splicing of mRNA molecules. In humans, there are usually multiple copies of another gene virtually identical in sequence, SMN2, which produces 10 % of complete SMN protein. It is known that increased expression of SMN2 improves the SMA phenotype. We have developed a multidisciplinary protocol, by which negative regulatory genes of SMN2 were discovered through an in silico approach based on analysis of gene expression profiles obtained from public transcriptomics experiments. We then knockdown these candidate genes in a Caenorhabditis elegans strain where the amount of SMN can be measured by fluorescence temporally and spatially. Thus, we have found that when a homolog of human SMPD1, a gene involved in sphingolipid metabolism, is inhibited by RNAi or specific drugs, SMN levels increase. We have also used motor neuron cultures of SMA patients, finding that the levels of SMPD1 mRNA and protein are increased in these cells. Furthermore, when they are treated with the SMPD1 inhibitor clomipramine, SMN levels also increase and a significant decrease in neurite degeneration is observed. Those results propose new therapeutic avenues for this devastating disease and represent a new method of finding modifiers and drugs for human diseases, GaliciAME association (I Ayudas de Investigación). Grants from: Instituto de Salud Carlos III (PI20/00098) to RMS; PID2023–148192OB-100/Ministerio de Ciencia, Innovación y Universidades, Gobierno de España to RMS and AG; Biomedical Research Talent grant from Diputació de Lleida-IRBLleida and Ajuts UdL per a la contractació de personal predoctoral en formació, convocatòria 2023, Universitat de Lleida, to MB; Serra Hunter Fellow from Generalitat de Catalunya to AG; Programa INVESTIGO 2022 finançat per la Unió Europea, Next Generation EU (AGAUR, Generalitat de Catalunya) to FCN; AMBL and MJM have been funded by “The C. elegans assay unit of the University Pablo de Olavide”
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inhibition of acid sphingomyelinase increases SMN levels and connects sphingolipid metabolism to Spinal Muscular Atrophy

  • Brokate Llanos, Ana
  • Beltran Perelló, Maria
  • Garzón, Andrés
  • Garcera, Ana
  • Miralles, María
  • Celma Nos, Ferrán
  • Campoy López, Alejandro
  • Soler i Tatché , Rosa Ma.
  • Muñoz, Manuel
  • Pérez Pulido, Antonio
Spinal Muscular Atrophy (SMA) is a moderately rare disease that causes progressive motor neuron degeneration and presents the highest neonatal death rate of all human genetic diseases. It is associated with the deletion or mutation of the SMN1 gene, encoding the SMN protein, mainly involved in the assembly of a ribonucleoprotein complex called Sm ring, essential for the splicing of mRNA molecules. In humans, there are usually multiple copies of another gene virtually identical in sequence, SMN2, which produces 10 % of complete SMN protein. It is known that increased expression of SMN2 improves the SMA phenotype. We have developed a multidisciplinary protocol, by which negative regulatory genes of SMN2 were discovered through an in silico approach based on analysis of gene expression profiles obtained from public transcriptomics experiments. We then knockdown these candidate genes in a Caenorhabditis elegans strain where the amount of SMN can be measured by fluorescence temporally and spatially. Thus, we have found that when a homolog of human SMPD1, a gene involved in sphingolipid metabolism, is inhibited by RNAi or specific drugs, SMN levels increase. We have also used motor neuron cultures of SMA patients, finding that the levels of SMPD1 mRNA and protein are increased in these cells. Furthermore, when they are treated with the SMPD1 inhibitor clomipramine, SMN levels also increase and a significant decrease in neurite degeneration is observed. Those results propose new therapeutic avenues for this devastating disease and represent a new method of finding modifiers and drugs for human diseases, GaliciAME association (I Ayudas de Investigación). Grants from: Instituto de Salud Carlos III (PI20/00098) to RMS; PID2023–148192OB-100/Ministerio de Ciencia, Innovación y Universidades, Gobierno de España to RMS and AG; Biomedical Research Talent grant from Diputació de Lleida-IRBLleida and Ajuts UdL per a la contractació de personal predoctoral en formació, convocatòria 2023, Universitat de Lleida, to MB; Serra Hunter Fellow from Generalitat de Catalunya to AG; Programa INVESTIGO 2022 finançat per la Unió Europea, Next Generation EU (AGAUR, Generalitat de Catalunya) to FCN; AMBL and MJM have been funded by “The C. elegans assay unit of the University Pablo de Olavide”
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition

  • Torres, Pascual
  • Rico-Ríos, Santiago
  • Ceron-Codorniu, Miriam
  • Santacreu-Vilaseca, Marta
  • Seoane-Miraz, David
  • Jad, Yahya
  • Ayala, Victòria
  • Mariño, Guillermo
  • Beltrán, Maria
  • Miralles, Maria P.
  • Andrés Benito, Pol
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • López-Otín, Carlos
  • Soler, Rosa M.
  • Povedano, Mónica
  • Ferrer, Isidro
  • Pamplona, Reinald
  • Wood, Matthew J. A.
  • Varela, Miguel A.
  • Portero-Otín, Manuel
Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disease with a mean survival time of three years. The 97% of the cases have TDP-43 nuclear depletion and cytoplasmic aggregation in motor neurons. TDP-43 prevents non-conserved cryptic exon splicing in certain genes, maintaining transcript stability, including ATG4B, which is crucial for autophagosome maturation and Microtubule-associated proteins 1A/1B light chain 3B (LC3B) homeostasis. In ALS mice (G93A), Atg4b depletion worsens survival rates and autophagy function. For the first time, we observed an elevation of LC3ylation in the CNS of both ALS patients and atg4b−/− mouse spinal cords. Furthermore, LC3ylation modulates the distribution of ATG3 across membrane compartments. Antisense oligonucleotides (ASOs) targeting cryptic exon restore ATG4B mRNA in TARDBP knockdown cells. We further developed multi-target ASOs targeting TDP-43 binding sequences for a broader effect. Importantly, our ASO based in peptide-PMO conjugates show brain distribution post-IV administration, offering a non-invasive ASO-based treatment avenue for neurodegenerative diseases., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. G.M. was supported by grants from Ministerio Ciencia e Innovación (Spain) (PID2021-127534OB-I00). M.P.-O. and R.M.S. were supported by grants from Instituto de Salud Carlos III (PI20/000155, PI23/00176 and PI20/00098). R.P. was supported by Generalitat de Catalunya (2021 SGR 00990). P.T. was supported by an Unzué-Luzón grant. P.T. received a Margarita Salas postdoctoral fellowship from the Spanish Ministry of Universities (Spanish Government) which was supported by NextGenerationEU. Work supported by IRBLleida Scientific and Technical Service of Immunohistochemistry.